Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well if that wasn’t the strangest thing on the planet?
My plan was to research the heck out of this thing and share it with who is on this weekend.
This way we can start Monday ahead of the pac.
There really are only two questions that I would like answers to. This company of course and it’s future and of course what my other message said. Much obliged and whatever I find out, it stays right here.
I have been doing a lot of studying on this company. I know that we are closer to the 52 week wow than the high. This sector is supposed to be picking up in this company looks pretty decent. What can we expect as far as mergers or stock forecast for 2020? Pretty legitimate not asking for million dollar tickers...
Where are we and where are we going....
You saw that, yes.
thanks but I do not have a photographic memory unfortunately.
Looks like you were taken down.
Fast!
But we’re smarter than that
That’s why I love this board. You don’t have to deal with scammers or flippers or anybody trying to feed you a line just to buy end so they can dump. You guys have already been very hospitable. There’s a certain company farmer that is going to buy 11% of a biotech company. If we can find out the ticker symbol on this biotech company,
it’s worth about 180% in the first three days and a bunch more coming after.
Right now the biotech price is very low.
If we can keep it to just us for now The ones here that are interested can get in before the world finds out about it.
Trust me,
I spent four hours digging and digging to find this ticker.
Nobody is leaking it.
Come on guys,
dig a little bit with me.
I promise you it will be worth it!
I put a lot of time in. As soon as I find it I will share on this page. And only this page! It’ll be taken down by Monday so it needs to happen. Everybody takes 15 minutes.
With the experience reading this,
I have no question we can get this ticker symbol.
Monday morning we will be locked and loaded!
Oh yes!
Hey gang,
Im a quiet holder but have a question driving me crazy!
The MU wait for chips was so Ridiculous even after having this giant to do in Las Vegas.
Do you know the people that paid all around the world to go to Las Vegas just to hear that ticker symbol was not given out at that meeting?
You had to purchase his book in order to get it.
As soon as I dug it up,
I gave it out to everybody.
Now this big Pharma company whoever they are,
are getting ready to purchase 11% of a biotech company.
It has not happened yet but I’m looking for the ticker symbol for the biotech company.
The Pharma company is already out of reach but the biotech company There’s a couple of very important patents making the merger happen quicker.
Does anybody know the biotech company ticker symbol?
I need something that’s going to climb and keep climbing.
On a sidenote,
before my wife finds out I lost just about everything on the stock that should have gone to 50 plus wish i had known they had trouble with their CEO and the CFO having private meetings putting the company under investigation and stopping all Trading for over a month. It trades for 1/10000 of a penny now. I put everything on it!!!
. If you can throw that out to me, you could possibly change my marriage LOL.
Thanks very much and good skill to everyone!
The only job that I have ever had that did not look forward to the weekends!!! Happy hunting!
I dont have pm but please use it if you can. Happy Holidays!
Thanks gang
Sweet Virginia Breeze
Thinking people are just taking profits today?
News: $NKTR 2 Stocks That Soared Monday While the Market Slumped
Are you in the holiday spirit yet? Well, obviously the stock market isn't, given its tepid performance on Monday. Most major indexes sagged, with many stocks sinking along with them. Monday's a good day to go positive, though, so I'm going to highlight two stocks that bucked this trend and incr...
Got this from NKTR - 2 Stocks That Soared Monday While the Market Slumped
News: $NKTR Why Nektar Therapeutics Stock Popped Today
Shares of Nektar Therapeutics (NASDAQ: NKTR) were up 11.4% as of 3:15 p.m. EST on Monday. The biotech presented data Sunday evening at the American Society of Hematology (ASH) annual meeting from a preclinical trial evaluating immunotherapy NKTR-255. Nektar also received a boost from news th...
Read the whole news NKTR - Why Nektar Therapeutics Stock Popped Today
News: $NKTR Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
SAN FRANCISCO , Dec. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented fr...
In case you are interested NKTR - Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
News: $NKTR Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
SAN FRANCISCO , Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammato...
Read the whole news NKTR - Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
News: $NKTR Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO , Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clin...
Got this from NKTR - Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
* * $NKTR Video Chart 10-08-2019 * *
Link to Video - click here to watch the technical chart video
Everything You Need For Your Premarket Including Nektar
Nektar had some manufacturing issues for its cancer drug, certainly hurting company credibility. Every day there is a Premarket Breakfast post with what's going on, why, gappers and sentiment. Today's Post is at
https://www.behindthebid.com/posts/premarket-breakfast-for-friday-august-9th
NKTR says two production lots of NKTR-214 were substandard—possibly causing the attenuated recent responses in PIVOT-02 compared to the early responses. Ouch.
Hmm…
https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-201500243.html
Nektar is hosting a conference call with analysts and investors today on which it will discuss quarterly results. On the call, the company will provide a specific update and discussion on its bempegaldesleukin clinical development program, including recent developments related to the manufacturing of bempegaldesleukin.
A trial in Germany is testing a neoantigen based vaccine (+/- Bempeg) in pts with locally advanced or metastatic melanoma, NSCLC, RCC (clear), UC or squamous cell carcinoma of head and neck, who did not achieve a CR with current standard of care immune checkpoint blockade https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002474-39/DE
News: $NKTR Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
SAN FRANCISCO , Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in comb...
Find out more Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
NKTR 4Q18 CC transcript:
https://finance.yahoo.com/news/nektar-therapeutics-nktr-q4-2018-140037448.html
ASCO-SITC Clinical Immuno-Oncology Symposium abstract
Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory environment, and antigen presentation. NKTR-214 increases CD8+ T cells and NK cells in the tumor microenvironment. The combination of NKTR-262 with NKTR-214 accesses innate and adaptive immunity to provide an abscopal response and systemic tumor immunity. The Phase 1b/2 REVEAL trial is enrolling.
Methods: In a 3+3 Phase 1 design, pts who are relapsed/refractory to ≥1 CPI receive escalating doses of intratumoral (IT) NKTR-262 followed by combined q3w treatment of IT NKTR-262 and fixed-dose intravenous (IV) NKTR-214 (0.006 mg/kg). Phase 1 will evaluate PK, safety, efficacy, and determine recommended Phase 2 dose. Scans are conducted every 9 wks (± 1 wk). Peripheral blood (PB) and tumor tissue are collected to measure biomarkers of immune activation. In Phase 2 expansion, NKTR-262 + NKTR-214 ± IV nivolumab (360 mg) will be assessed in specific tumor cohorts of IO-naïve and experienced pts.
Results: As of 06 Nov 2018, 11 pts had received at least one cycle of NKTR-262 + NKTR-214 therapy. 7/11 pts were efficacy evaluable with at least one on-treatment scan (4 MEL, 2 SARC, 1 CRC). 2/4 R/R melanoma pts had uPRs with 100% (scan 2) and 40% (scan 1) reductions in target lesions per RECIST 1.1, respectively. Both patients remain on treatment. Two SARC pts had stable disease at scan 1. No pts experienced G3 or higher TRAEs or immune-related adverse events (AEs). Most common G1-2 AEs were transient flu-like symptoms. Gene expression analysis of tumor and PB show dose-dependent induction (4 to 16-fold) of TLR target genes. Consistent with the mechanism of action for NKTR-214, PB flow cytometry shows an average 13-fold increase from baseline in Ki67+ CD8+T cells in 6 pts.
Conclusions: NKTR-262 + NKTR-214 engage the immune activation cascade from local tumor antigen production to anti-tumor T cell response. Initial dose levels of NKTR-262 with fixed-dose NKTR-214 were well-tolerated with early evidence of clinical activity. These data support continued evaluation of the combination +/- nivolumab. Clinical trial information: NCT03435640
https://meetinglibrary.asco.org/record/170420/abstract
Dr. Zalevsky will provide updates on NKTR-214 during the preclinical plenary session at IO360 https://theconferenceforum.org/conferences/immuno-oncology-360/overview/
From this: ''With NKTR-214, a kinetically engineered IL-2 receptor agonist, the B2M knockout cell lines also overcame resistance to PD-1 inhibition and it increased survival significantly in these cell lines.'' https://www.targetedonc.com/conference/sitc-2018/two-rapidfire-abstracts-break-down-biomarkers-of-response-and-resistance
SITC data—Melanoma PIVOT-02 ORR=53%* (20*/38)—24% (9/38) CRs:
PR:
https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-presents-new-clinical-and-preclinical-data
CC slides:
https://t.co/cnESfELNnp
Of the 33 patients with known (pre-treatment) PD-L1 status, ORR was: 43% (6/14) in PD-L1-negative patients; and 68% (13/19) in PD-L1-positive patients.
*One additional responder relative to the SITC abstract, which was 50% (19/38).
I had a few too many. What I should have added is that the reason I don't own more shares is due to 'issues' I have with management. Not long after O'Connor became CEO I sold a number of them.
NKTR 3Q18 results—cash=$2.0B:
https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-211000969.html
The previous post is in error regarding the cash balance—please ignore it.
NKTR 3Q18 results—cash=$353M:
https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-211000969.html
NKTR, PFE ink clinical-trial collaboration for NKTR-214 with PFE compounds:
https://finance.yahoo.com/news/clinical-oncology-collaboration-between-nektar-133000524.html
Under the new collaboration, Pfizer will initiate a Phase 1b/2 clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214. Nektar, Pfizer and their respective partners will each maintain global commercial rights to their respective medicines.
You own ONCS because of management?
$GNCA*, $ONCS*, $GRTS, $REPL, $DVAX, $ADRO** and $IDRA*** are some. I can't see me buying $NKTR again until after SITC.
* I hold a small position due to management.
** I will wait and see what data is presented at SITC.
*** A risky bet.
Which biotech companies are you long? TIA
Melanoma Bridge Conference: 'Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma**, Adi Diab' https://www.melanomabridge.org/2018A/scientific-program.php
Appears that institutions have made up their mind again. Sell first , ask questions later.
On second thought, #msg-144383492 is a better explanation for today's selloff.
The shareholder is always the last one to know anything. The price action is very similar to what happened years and years ago when Exubera (inhalable insulin) crashed and burned after a similar run up in price.
Hope folks weren't averaging down on this company.
After examining the "rebuttal" text more closely, I'm certain that it's not actually from NKTR.
If that's a real email response from the company, it's material information, and hence one would expect NKTR to issue an 8-K filing.
Someone emailed the IR department and posted the response in the S/A article comments section. It can also be found on the Yahoo board https://finance.yahoo.com/quote/NKTR/community?p=NKTR Plainview has issued a rebuttal https://s3.amazonaws.com/plainviewllc/Nektar+Therapeutics+Report+2.pdf
3 different posters on the NKTR YMB "Conversations" board reported that it was the response they received from NKTR's IR department. It was reposted on S/A in the Comments section to the Plainview's S/A version of its attack article. FWIW (and I haven't had time to review) here is the link to Plainview's rebuttal of the NKTR response:
https://s3.amazonaws.com/plainviewllc/Nektar+Therapeutics+Report+2.pdf
Where is that from?
This is the company's response to the short attack. I've decided to copy and paste the full.
''The report was lengthy and filled with what was positioned to be science but were actually inaccurate scientific inaccuracies and miscalculations. Below, we chose to focus on the major inaccuracies to point out the author’s flaws in the central premise. My team and I are available for a call today if needed – please let me know if you need it.
With our partner Bristol-Myers Squibb, we are developing NKTR-214 with nivolumab in 9 tumor types in over 20 registrational trials. We have a melanoma Phase 3 trial that has already been initiated and several additional registrational trials that are planned to start in renal cell carcinoma and bladder cancer by the end of the year. Clearly, the commitment of our two companies to the long-term development of the combination underscores our conviction in the combination results and our belief in the potential value of NKTR-214 and Opdivo to patients and physicians in the fight against cancer.
As we stated on our last financial results call, we look forward to presenting mature data from the fully enrolled 38-patient Stage IV melanoma cohort from PIVOT at the upcoming SITC conference in November. The data will be presented in an oral presentation on Friday, November 9th in the Cytokines Reinvented session. As data from the PIVOT cohorts mature over the next six to 18 months, Nektar and Bristol are planning to present each of the data sets at various medical meetings, including tumor-specific conferences, in the lung, melanoma, GU and breast cancer specialty areas.
The report written and issued by Plainview has a flawed central premise, contains many scientific inaccuracies, and deliberately omits published data that did not support its premise. The author did not conduct diligence with the company or the authors of peer-reviewed published data on NKTR-214. While the report is long and cites a number of references, many references are omitted and those cited are selective. As a result, we focused on the most egregious inaccuracies and omissions found in the executive summary.
The writer uses as his premise in multiple areas that lymphocyte levels following treatment with NKTR-214 did not increase sufficiently. However, the writer ignores a more complete 2018 dataset presented for NKTR-214 to make this argument. Instead, he cites 2017 data from a handful of early patients enrolled in the dose-escalation stage of the PIVOT trial (ASCO 2017) and references only a 30-50% increase in lymphocyte levels. At ASCO 2018, the company presented comprehensive lymphocyte level data for over 200 patients who were treated with the recommended Phase 2 dose of NKTR-214. The data show an increase over baseline after first cycle of >100% (achieving a level of >200% of baseline) and in subsequent cycles with NKTR-214 lymphocyte levels range up to a 200% increase over a baseline (achieving a level of 300% of baseline) which is then sustained over 10 cycles of therapy (over 200 days): Source: ASCO 2018 --- graph notes added: A: ~200% of baseline, B: ~300% of baseline
These ASCO 2018 results are concordant with what is known from the literature about lymphocyte increases following HD-IL-2. Contrary to the author’s conclusion, the pharmacodynamic effect for NKTR-214 is in fact consistent with modeling expectations for HD-IL-2. However, NKTR-214 maintains an essential difference to HD-IL-2 in that it is very-well tolerated and allows for continuous dosing (note the 10 cycles of therapy shown in the chart above). This provides a longer duration of sustained IL-2 receptor agonism and sustained increased lymphocyte levels, much longer in duration than the short increase provided by one to two cycles of HD-IL-2.
Overall Response Rate for Monotherapy HD-IL-2 vs NKTR-214
The body of selected data listed in report with high-dose IL-2 is in first-line previously untreated patients. ORR reported in the older literature vary but the studies were conducted prior to the availability of TKI therapies, BRAF therapies and checkpoint inhibitors. As is well-known, the IL-2 response rates were achieved at the expense of safety in these relatively healthy first-line patients. As an example, the author omits Phase 1 clinical data in second-line RCC patients where high-dose IL-2 was evaluated and had no responses. An important retrospective analysis by Dr. Daniel Cho (Journal of Immunotherapy 2009), highlights 28 patients who received high-dose IL-2 following treatment with TKI therapy/bevacizumab therapy. Only 3 of 28 or 11% experienced stable disease and there were no PRs or CRs (unconfirmed or otherwise). Only 1 of 23 patients could receive a second cycle of high-dose IL-2 and 26% of patients experienced severe cardiovascular toxicities, including cardiac arrest and acute pulmonary edema.
NKTR-214 was evaluated in a dose-ranging monotherapy trial in 28 patients with advanced, pre-treated cancer with a median number of prior therapies of 2 (and a range of 1-12). The breakout for pre-treatment was as follows: 16 (57.1%) had received targeted therapy; 16 (57.1%) had received an immune checkpoint inhibitor; and 6 (21.4%) had received an immune checkpoint inhibitor in addition to other immunotherapy. Tumor shrinkage was observed in 32% or 9 out of 28 patients (ranging from 2-30% tumor shrinkage), with a best response of stable disease in 50% or 14/28 patients. One patient experienced an unconfirmed partial response (a patient with advanced renal cell carcinoma who was treated with a prior TKI regimen). Another patient with pre-treated renal cell carcinoma had a 40% reduction on the right adrenal gland at the first on-treatment scan (the overall response was stable disease). Durable, stable disease > 1 year was also seen in 2 patients who continued on therapy for over one year. One patient with metastatic melanoma, previously treated with ipilimumab and a BRAF inhibitor, received 25 cycles of NKTR-214 and had durable stable disease (SD) for 15 months. A second patient with metastatic RCC, who had progressed on HD-IL-2 and was refractory to single-agent OX40 and nivolumab, was treated with 19 cycles of NKTR-214 and had durable SD for 13 months. Every patient evaluated showed evidence of immune activation and these effects were reproduced with repeated administration. Only 21% of patients experienced a G3 toxicity but these were reversible and short-lived; there were no G4/5 AEs reported. (SITC 2016, ASCO 2017 and SITC 2017)
Finally, the author quotes a paper from 2005 by Maker et al in order to disparage the combining of an IL-2 mechanism with a checkpoint inhibitor and its clinical benefit. However, the writer omits the conclusions from a later paper published by Prieto et al in 2012 which analyzed the same patients cited in the Maker study in a longer-term follow-up and highlighted the long-term clinical benefit of the combination, namely a high rate of durable complete responses achieved in these patients.
The author mis-casts the receptor-bias inherent to NKTR-214 by pulling a partial figure from a published peer-reviewed publication (2017 Charych et al PLOS ONE). If the full figure is viewed, it is clear that NKTR-214 exhibits a biased receptor occupancy favoring the IL-2 beta-gamma receptor. As a result of its bias, direct comparison of exposure (AUC) from PK evaluation of NKTR-214 active drug vs HD-IL-2 is not relevant.
Further, HD-IL-2 clears rapidly and requires TID dosing. NKTR-214 has a prodrug design with a long half-life and q3 week dosing. Given the difference in mechanisms, an analysis of PD changes, notably the increases in lymphocyte levels after drug administration (or the desired effects of dosing) is the more important measure of adequate dose administration. Nektar has highlighted achievement of this desired effect in data presented at ASCO 2018 (refer to above section on Lymphocyte Effects).
NKTR-214 was designed to avoid Treg accumulation in the tumor microenvironment. Our earliest preclinical studies demonstrated the ability to promote transient Treg elevations in the peripheral blood, but not the tumor. Inherent to its design, it is necessary to preserve some binding to IL-2R-alpha because that receptor is needed for T-cell priming reactions in the lymph node.
The statements made around TIL increases with NKTR-214 are inaccurate; in the monotherapy trial, substantial increases in intratumoral CD8+ T cells were reported with no intratumoral CD4+ T regulatory expansion (SITC 2016, ASCO 2017 and SITC 2017). These data have been published at numerous congresses.
As stated above, NKTR-214 causes elevations in lymphocytes. These elevations are seen in blood and in tumor. The fact is that substantial lymphocyte increases with NKTR-214 were observed in the periphery so this can’t be used to refute the reported TIL increases with NKTR-214 in the published data as the author attempts.
In the tumor, we have observed high concordance of TIL increases with monitoring using multiple methods; immunohistochemistry (IHC), fresh tissue flow cytometry, and T cell DNA analysis (a method that compares T cell-specific DNA vs non T cell-specific DNA to quantify the mass of T cells in tumor tissue) and all three methods have produced concordant results (manuscript in preparation). The use of several methods is critical as it important to observe concordance across these methods to increase confidence in the results.
The author uses older SITC 2016 data rather than referring to more recent publications. At ASCO 2018, Nektar reported IHC data on TIL elevations from 33 tumor biopsies in PIVOT patients at the RP2D. IHC is the most common method used in the historical literature for other agents and allows for comparison to nivolumab. The author uses a Tumeh paper to support an argument that TIL increases are observed with nivolumab. However, the author declines to point out that the Tumeh paper only demonstrates that select patients with elevated baseline TILs were able to experience a small 2-fold or less increase in TILs following nivolumab. The reality is that a 10-fold increase in TILs was observed following treatment with NKTR-214 even in patients with low baseline TILs which has not been shown with nivolumab. This is consistent with the mechanism of action of NKTR-214.
Unlike the epacadostat open label single arm trials, the PIVOT trial of NKTR-214 and Opdivo has independent blinded central data review for ORR. Nektar and BMS have stated there is a high concordance between the investigator-assessed and independent review. As the separate tumor cohorts are independently presented, such as at the upcoming SITC meeting, Nektar and BMS plan to present the investigator and independent ORR side-by-side for full transparency. The NKTR-214 and nivolumab PIVOT trial is enrolling Stage IV patients and did not enroll Stage III patients as the epacadostat studies did.
Nektar has demonstrated translational data from NKTR-214 monotherapy and the nivolumab combination studies that clearly differentiates from the mechanism of IDO inhibition. NKTR-214 promotes TIL increases, proliferation of lymphocytes (Ki67+ expressing), increases in PD-1 and ICOS expression, and increases in PD-L1 in the tumor. The MOA of NKTR-214 changes the immune system and the tumor microenvironment in a beneficial way that is non-overlapping and complementary with anti-PD1 checkpoint antibodies. We’ve observed high response rates with NKTR-214 and nivolumab in baseline PD-L1 negative patients, deepening of responses over time, and a low immune-mediated AE profile which is critically important in an I-O combination therapy.''
A neoantigen vaccine (VB10.NEO) and 214 will be tested in 10 patients with SCCHN http://www.vaccibody.com/vaccibody-announces-clinical-collaboration-agreement-with-nektar-therapeutics-for-evaluation-of-vaccibodys-personalized-cancer-neoantigen-vaccine-in-combination-with-nektars-cd-122-b/
A trial with BXCL701 (DPP 8/9 & FAP inhibitor), 214 and a PD-1 inhibitor will be underway in PDAC soon https://ir.bioxceltherapeutics.com/press-releases/detail/54/bioxcel-therapeutics-expands-immuno-oncology-partnership
Also unconfirmed reports of a preclinical collaboration with Affimed.
15% drop this week. Me thinks something not quite as rosy as predicted is causing sell off.
The CC was routine. A lot of clinical news-flow in next 6-18 months.
Nothing negative from last earning report....stock back on the move fueled in part by short covering.
No I sold awhile back because of so much inside selling
Think you're better than me?
I had this glad I took my profits after my double
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
295
|
Created
|
10/20/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |